Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 8 Observational 1

Sponsor

Conditions

Carcinoma, Hepatocellular 18 Cholangiocarcinoma 3 Thyroid Neoplasms 2 Recurrence 1 Neoplasms, Glandular and Epithelial 1 Neoplasms 1 Liver Neoplasms 1 Liver Diseases 1 Coitus 1 Carcinoma, Renal Cell 1 Carcinoma 1 Biliary Tract Neoplasms 1

Interventions

Surgical Procedures, Operative 7 Liver Transplantation 5 Lenalidomide 4 Blood Specimen Collection 4 pomalidomide 3 Neoadjuvant Therapy 3 Liquid Biopsy 3 gilteritinib 2 Therapeutics 2 Rituximab 2 Proteasome Inhibitors 2 Observation 2 Mohs Surgery 2 Mitomycin 2 Magnetic Resonance Spectroscopy 2 Immunotherapy, Adoptive 2 Immunoconjugates 2 High-Throughput Nucleotide Sequencing 2 Fluorouracil 2 Drug Therapy 2 DNA, Mitochondrial 2 Brentuximab Vedotin 2 Bendamustine Hydrochloride 2 Antibodies, Monoclonal 2 Antibodies, Bispecific 2 Amplified Fragment Length Polymorphism Analysis 2 trametinib 1 romidepsin 1 nedaplatin 1 lenvatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Recurrence × lenvatinib × Clear all

NCT06253364 2024-03-13

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Tongji Hospital

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡